Clinical evaluation of EBV serology in American patients with nasopharyngeal carcinoma.
There is now extensive immunological, biological and biochemical evidence to support a possible etiological relationship between EBV and NPC in patients from different geographical locations. Besides providing information on the question of etiology, the results from immunological investigations suggest that antibodies to some of the EBV-associated antigens might also be of clinical importance in the diagnosis and prognosis of NPC. To determine the possible clinical application of EBV serology to American NPC, sera from patients seen at the Mayo Clinic and the National Institutes of Health were examined for antibodies to EBV-associated antigens in an effort to identify those parameters which most reliably distinguish NPC from other types of cancer. The results show that high antibody titres to EBV-induced EA and the presence of antibody to EBV antigens in the IgA immunoglobulin fraction were the two most specific discriminating parameters, although neither was infallible. These findings are discussed in relation to future studies that are needed in order to determine the potential clinical value of EBV serology to the diagnosis and prognosis of NPC.
D000914:Antibodies, Viral / Q000032:analysis*; D000956:Antigens, Viral; D002213:Capsid / Q000276:immunology; D002277:Carcinoma / Q000097:blood / Q000276:immunology* / Q000628:therapy; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis*; D009303:Nasopharyngeal Neoplasms / Q000097:blood / Q000276:immunology* / Q000628:therapy; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D014481:United States
D000914:Antibodies, Viral; D000956:Antigens, Viral; D007070:Immunoglobulin A